Last updated: February 19, 2026

Ferrous citrate, Fe-59, also known as Iron-59 citrate, is a radiopharmaceutical primarily used for diagnostic purposes in iron metabolism studies. Its market is characterized by niche applications, driven by the specialized nature of nuclear medicine diagnostics and the limited number of facilities equipped for its use. The financial trajectory is intrinsically linked to the demand for these specific diagnostic procedures, research funding, and regulatory approvals for new applications.

What is the current market size and growth projection for Ferrous Citrate, Fe-59?

The market for ferrous citrate, Fe-59, is a specialized segment within the broader radiopharmaceuticals market. Precise global market size figures for this specific isotope are not readily available in public domain market research reports, as it is often aggregated within broader categories like diagnostic radiopharmaceuticals or iron chelators. However, industry analysts estimate the global radiopharmaceuticals market to be valued at approximately $5 billion in 2023, with projections to reach $10 billion by 2030, growing at a compound annual growth rate (CAGR) of around 10% [1]. Within this, diagnostic radiopharmaceuticals represent a significant portion.

Ferrous citrate, Fe-59, specifically, is not a high-volume product. Its demand is driven by clinical research and specialized diagnostic procedures for conditions like:

Iron Deficiency Anemia: Investigating absorption and kinetics.
Hemochromatosis: Assessing iron overload and treatment efficacy.
Gastrointestinal Bleeding: Identifying the source of blood loss.
Hematological Disorders: Studying red blood cell production and destruction [2].

Given its diagnostic focus and the specialized nature of nuclear medicine, the growth for ferrous citrate, Fe-59, is projected to be more modest than the overall radiopharmaceuticals market. A realistic growth projection would likely be in the low to mid-single digits (2-4% CAGR) over the next five to seven years, contingent upon advancements in diagnostic techniques and the continued use of iron metabolism studies in clinical practice and research. Factors influencing this projection include:

Technological Advancements: Development of alternative, non-radioactive diagnostic methods could temper growth.
Clinical Adoption: Increased recognition and integration of Fe-59 studies into standard diagnostic protocols.
Research Funding: Continued investment in hematology and gastrointestinal research will directly impact demand for research-grade Fe-59 citrate.
Regulatory Environment: Approvals for expanded diagnostic indications could stimulate growth.

Who are the key manufacturers and suppliers of Ferrous Citrate, Fe-59?

The production and supply of radiopharmaceuticals, including ferrous citrate, Fe-59, are highly regulated and require specialized infrastructure and expertise. The market is dominated by a limited number of established radiopharmaceutical companies. Key players globally include:

GE HealthCare: A major provider of medical imaging and nuclear medicine products.
Cardinal Health: Offers a broad range of pharmaceutical products, including radiopharmaceuticals, through its nuclear pharmacy network.
Curium Pharma: A dedicated radiopharmaceutical company with a significant portfolio of diagnostic and therapeutic products.
Nordion (now part of Sotera Health): A long-standing supplier of radioisotopes and related products.
ITM Isotopen Technologien München AG: Specializes in the production and development of radioisotopes for medical applications.

These companies typically operate global distribution networks and adhere to strict quality control and regulatory standards set by bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The supply chain for Fe-59 is particularly sensitive due to the short half-life of the isotope (44.5 days) [3], requiring efficient logistics and production planning. Manufacturers often produce Fe-59 citrate in response to specific orders or projected demand from nuclear medicine centers and research institutions.

What is the patent landscape for Ferrous Citrate, Fe-59 and related applications?

The patent landscape for ferrous citrate, Fe-59, itself is likely to be less active in terms of novel composition of matter patents, given that it is a well-established chemical entity and radioisotope. Patents are more likely to focus on:

Novel Formulations: Improved delivery systems, stabilization of the radiopharmaceutical, or formulations for enhanced imaging.
Manufacturing Processes: More efficient or cost-effective methods for producing high-purity Fe-59 citrate or for incorporating Fe-59 into citrate.
New Diagnostic Applications: Patents covering specific diagnostic protocols, methods for interpreting Fe-59 citrate scans, or its use in diagnosing particular diseases or conditions.
Combination Therapies or Diagnostics: Patents related to the use of Fe-59 citrate in conjunction with other agents or modalities.

A comprehensive patent search reveals a history of patents related to iron isotopes and their medical applications. For example, patents exist concerning methods for producing radioisotopes, imaging techniques, and diagnostic kits involving iron isotopes. However, a significant number of older, foundational patents related to basic iron isotope production or early diagnostic uses have likely expired.

Current patent activity would be concentrated among the major radiopharmaceutical manufacturers and academic research institutions exploring novel uses or improved delivery. For instance, recent patent filings might pertain to:

Methods for producing a stable iron-59 citrate complex for enhanced shelf-life and reduced radiation exposure during handling [4].
Diagnostic kits incorporating ferrous citrate, Fe-59, along with reagents for sample preparation and analysis in specific gastrointestinal studies.
Protocols for using ferrous citrate, Fe-59, in conjunction with other imaging agents to differentiate between various types of anemia or iron absorption disorders.

The expiration of key patents can open opportunities for generic manufacturers or new entrants, though the specialized nature of radiopharmaceuticals creates significant barriers to entry related to regulatory compliance and manufacturing expertise. Companies looking to innovate in this space would focus on the application and formulation patents.

What are the regulatory considerations and approval pathways for Ferrous Citrate, Fe-59?

Ferrous citrate, Fe-59, as a radiopharmaceutical intended for human use, is subject to stringent regulatory oversight. In the United States, this falls under the purview of the Food and Drug Administration (FDA). The approval pathway typically involves demonstrating safety and efficacy for its intended diagnostic use.

Key Regulatory Considerations:

Manufacturing and Quality Control: Facilities producing Fe-59 citrate must comply with Current Good Manufacturing Practices (cGMP). This includes rigorous control over raw materials, production processes, purity, and batch-to-batch consistency [5].
Radioactive Materials Handling and Licensing: The handling, storage, transport, and disposal of radioactive materials like Fe-59 are governed by the Nuclear Regulatory Commission (NRC) in the U.S. and equivalent bodies internationally. Facilities using Fe-59 citrate must hold specific licenses.
Investigational New Drug (IND) Application: For new diagnostic uses or novel formulations, an IND application is required to allow for clinical trials in humans.
New Drug Application (NDA) or Abbreviated New Drug Application (ANDA): For marketing approval, a full NDA is typically required for a new drug. If a generic version of an already approved Fe-59 citrate product were to be developed, an ANDA might be possible, demonstrating bioequivalence and comparable manufacturing standards.
Labeling Requirements: Product labeling must clearly state the radioactive content, half-life, storage conditions, administration instructions, potential risks, and contraindications.

Approval Pathways:

Existing Approved Product: If ferrous citrate, Fe-59, is already approved for a specific diagnostic indication, the pathway for its continued use and sale by approved manufacturers involves maintaining cGMP compliance and adhering to post-market surveillance requirements.
New Indications: If a manufacturer wishes to market Fe-59 citrate for a new diagnostic indication (e.g., a previously unapproved application), they would need to conduct clinical trials to demonstrate safety and efficacy for that specific indication. This would typically involve submitting an IND, conducting trials, and then filing an NDA.
New Formulations or Manufacturing Processes: Significant changes to an approved formulation or manufacturing process may require regulatory review and approval, potentially involving bioequivalence studies or new efficacy data depending on the nature of the change.

The short half-life of Fe-59 means that production and approval cycles need to be efficient. Regulatory agencies often have pathways for expediting the review of radiopharmaceuticals used for critical diagnostic purposes.

What are the major clinical applications and their impact on demand?

The primary clinical applications of ferrous citrate, Fe-59, are diagnostic, focusing on the evaluation of iron metabolism and gastrointestinal function. These applications directly drive demand for the radiopharmaceutical.

Major Clinical Applications and Demand Drivers:

Iron Absorption Studies:
- Application: Measuring the rate and efficiency of iron absorption from the gastrointestinal tract. This is crucial for diagnosing conditions of malabsorption, such as celiac disease or inflammatory bowel disease, and for assessing the effectiveness of iron supplementation or bariatric surgery protocols.
- Demand Impact: High demand from gastroenterology, internal medicine, and research settings investigating nutritional deficiencies and gastrointestinal disorders.
Gastrointestinal Blood Loss Localization:
- Application: Identifying the site of chronic or occult gastrointestinal bleeding. After oral or intravenous administration, Fe-59 citrate can be tracked using external detectors to pinpoint the location of blood loss.
- Demand Impact: Essential for patients with unexplained anemia or suspected bleeding where endoscopic or radiological methods are inconclusive. Demand is consistent in specialized diagnostic centers.
Red Blood Cell Survival and Production Studies:
- Application: Used to evaluate the lifespan of red blood cells and assess erythropoiesis (red blood cell production). This helps in diagnosing hemolytic anemias (premature destruction of red blood cells) and aplastic anemias (impaired production).
- Demand Impact: Primarily utilized in hematology departments and research institutions focused on blood disorders.
Iron Metabolism and Kinetics Research:
- Application: Fe-59 citrate is a valuable tool in preclinical and clinical research to understand the complex pathways of iron absorption, distribution, utilization, and storage within the body.
- Demand Impact: Demand from academic research institutions and pharmaceutical companies conducting studies related to iron overload disorders (e.g., hemochromatosis), iron deficiency, and the development of new iron-related therapeutics.

The impact of these applications on demand is significant but specialized. Unlike broad-spectrum diagnostic agents, Fe-59 citrate is reserved for specific diagnostic questions where other methods are insufficient. The continued prevalence of iron deficiency anemia globally, coupled with advancements in understanding iron metabolism, sustains a baseline demand. However, the advent of newer, potentially non-radioactive imaging techniques or advanced laboratory markers for iron status could pose a competitive threat and influence future demand growth.

What is the competitive landscape and potential for market disruption?

The competitive landscape for ferrous citrate, Fe-59, is characterized by high barriers to entry due to stringent regulatory requirements, specialized manufacturing capabilities, and the need for a robust, secure supply chain for radioactive materials. The market is oligopolistic, with a few major global radiopharmaceutical suppliers dominating.

Key Competitive Factors:

Product Quality and Purity: Ensuring high isotopic and radiochemical purity is paramount.
Reliability of Supply: Consistent availability is critical due to the short half-life and specialized nature of the product.
Regulatory Compliance: Adherence to cGMP and radioactive material handling regulations is non-negotiable.
Distribution Network: Efficient logistics to deliver products with short shelf-lives to geographically dispersed nuclear medicine facilities.
Technical Support: Providing expertise and support to end-users in handling and administering the radiopharmaceutical.

Potential for Market Disruption:

Market disruption for ferrous citrate, Fe-59, is less likely to come from direct competitors offering a different form of Fe-59 citrate and more likely from:

Alternative Diagnostic Modalities:
- Non-Radioactive Imaging: Advancements in MRI, PET/CT (with different tracers), or ultrasound could offer alternative ways to assess iron distribution or gastrointestinal function without the use of ionizing radiation.
- Advanced Biomarkers: Development of highly sensitive and specific blood or genetic tests that can accurately diagnose iron metabolism disorders or identify bleeding sites without the need for imaging.
New Therapeutic Agents: While Fe-59 citrate is diagnostic, developments in iron-chelating therapies or iron replacement therapies that indirectly reduce the need for detailed iron metabolism studies could indirectly affect demand for diagnostic agents.
Changes in Reimbursement Policies: Shifts in how healthcare payers reimburse for nuclear medicine procedures versus alternative diagnostic tests could significantly impact demand. If Fe-59 citrate procedures become less attractive financially, demand could decrease.
Technological Advancements in Isotope Production: Breakthroughs in producing short-lived isotopes like Fe-59 more efficiently or locally (e.g., via smaller cyclotrons, though Fe-59 is typically produced in nuclear reactors) could alter the supply chain dynamics, but this is a complex area for Fe-59 specifically.

Given the established role of Fe-59 citrate in specific diagnostic niches, a complete displacement is unlikely in the short to medium term. However, sustained innovation in competing diagnostic technologies represents the most significant long-term threat to the market for this radiopharmaceutical.

What is the financial outlook and investment potential?

The financial outlook for ferrous citrate, Fe-59, is that of a stable, niche market with modest but consistent revenue streams. Investment potential is limited to companies already entrenched in the radiopharmaceutical sector or those seeking to develop complementary diagnostic tools or research applications.

Financial Outlook:

Revenue Stability: Demand for Fe-59 citrate is driven by established diagnostic needs and ongoing research. This provides a predictable, albeit limited, revenue base for manufacturers.
Pricing: As a specialized, low-volume product requiring extensive regulatory compliance and specialized manufacturing, pricing per unit is relatively high. Profit margins are likely to be healthy for established producers who have amortized their R&D and infrastructure costs.
Limited Growth: Significant revenue growth is unlikely without major breakthroughs in new indications or a substantial increase in the adoption of Fe-59 based diagnostics over alternative methods. Growth is primarily tied to the broader trends in nuclear medicine and hematology research.
Operational Costs: The primary financial challenges lie in maintaining the high operational costs associated with radioactive material production, quality control, regulatory compliance, and specialized logistics.

Investment Potential:

Niche Investment: Direct investment opportunities in ferrous citrate, Fe-59, production are rare. Investment is more likely to be channeled through larger radiopharmaceutical companies that have Fe-59 citrate as part of a broader portfolio.
Strategic Acquisition: Smaller companies developing novel applications or improved formulations for Fe-59 citrate might become acquisition targets for larger players looking to expand their diagnostics offerings.
Research & Development Focus: Investment is better directed towards companies and institutions actively researching:
- New applications for iron metabolism diagnostics.
- Improved imaging or analytical techniques related to iron.
- Non-radioactive alternatives that address similar clinical questions.
High Barriers to Entry: The significant capital investment and regulatory hurdles make it difficult for new entrants to compete, thus protecting incumbent players but also limiting broader investment diversification within this specific product.

Overall, the financial trajectory of ferrous citrate, Fe-59, is one of steady demand in its established niches rather than explosive growth. Investment considerations should focus on the long-term stability of these niches against evolving diagnostic technologies and the strategic positioning of established players.

Key Takeaways

Ferrous citrate, Fe-59, operates within a specialized segment of the radiopharmaceutical market, with demand driven by niche diagnostic applications in iron metabolism and gastrointestinal studies.
The market is characterized by limited competition, with a few major global radiopharmaceutical suppliers dominating production and distribution.
Patent activity focuses on novel formulations, manufacturing processes, and new diagnostic applications rather than the core compound itself.
Stringent regulatory oversight by bodies like the FDA and NRC governs manufacturing, handling, and approval pathways.
Demand is directly linked to the clinical utility in diagnosing iron absorption issues, gastrointestinal bleeding, and hematological disorders.
Potential market disruption arises primarily from advancements in alternative, non-radioactive diagnostic modalities and imaging techniques.
The financial outlook is for stable, modest revenue streams, with investment potential concentrated within established radiopharmaceutical companies rather than direct opportunities in Fe-59 citrate production.

Frequently Asked Questions

1. What is the primary difference between ferrous citrate, Fe-59, and other iron supplements?

Ferrous citrate, Fe-59, is a radioactive isotope of iron used for diagnostic purposes, specifically to track iron absorption and metabolism in the body. It is not an iron supplement intended for therapeutic iron replenishment. Standard iron supplements contain stable isotopes of iron (e.g., ferrous sulfate, ferrous gluconate) and are designed to increase the body's iron stores.

2. How long is the shelf-life of ferrous citrate, Fe-59, and what are the implications?

Ferrous citrate, Fe-59, has a half-life of approximately 44.5 days. This means that the radioactivity decays over time. The implication is that manufacturers must produce and distribute the product efficiently, and end-users must utilize it within a specific timeframe after production to ensure adequate radioactivity for diagnostic imaging and studies. This necessitates careful inventory management and timely delivery.

3. Are there any non-radioactive alternatives for studying iron absorption that can replace Fe-59 citrate?

While Fe-59 citrate remains a gold standard for precise quantitative measurements of iron absorption kinetics, alternative and complementary diagnostic methods exist. These include measuring serum ferritin, transferrin saturation, hepcidin levels, and C-reactive protein to assess iron status. For studying gastrointestinal bleeding, endoscopy and imaging techniques like capsule endoscopy or CT angiography are also utilized. However, for detailed kinetic studies, Fe-59 citrate often provides unique insights.

4. What are the risks associated with using ferrous citrate, Fe-59?

As a radiopharmaceutical, the primary risk associated with ferrous citrate, Fe-59, is exposure to ionizing radiation. The dose of radiation is carefully controlled to be as low as reasonably achievable (ALARA) while still providing diagnostic information. Potential side effects are generally related to the diagnostic procedure itself or the underlying condition being investigated, rather than direct toxicity from the citrate molecule. Risks are minimized through strict adherence to safety protocols and by using the lowest effective dose.

5. How is the cost of ferrous citrate, Fe-59, determined?

The cost of ferrous citrate, Fe-59, is influenced by several factors, including the expenses associated with radioisotope production, specialized manufacturing under cGMP conditions, rigorous quality control, regulatory compliance, licensing, and the logistics of handling and transporting radioactive materials with short shelf-lives. The niche demand and high development and operational costs contribute to its relatively high price compared to non-radioactive pharmaceuticals.

Citations

[1] Grand View Research. (2023). Radiopharmaceuticals Market Size, Share & Trends Analysis Report By Type (Diagnostic, Therapeutic), By Type of Radioisotope (Technetium, Iodine, Gallium, Fluorine, Others), By Application, By End-use, And Segment Forecasts, 2023 - 2030. [2] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Iron Metabolism Disorders. U.S. Department of Health and Human Services. [3] National Institute of Standards and Technology. (n.d.). Nuclear Data: Iron-59. Retrieved from NIST website. [4] (Hypothetical patent example based on industry trends). [5] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP). Retrieved from FDA website.

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	4
DailyMed Link:	ferrous citrate, fe-59 at DailyMed

Sponsor	Phase
SBI Pharmaceuticals Co, Ltd.	PHASE2
Emerald Clinical Inc.	PHASE2
University of Oxford	PHASE2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt	FERROUS CITRATE FE 59	ferrous citrate, fe-59	INJECTABLE;INJECTION	016729-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Ferrous citrate, fe-59 - Generic Drug Details

What are the generic sources for ferrous citrate, fe-59 and what is the scope of freedom to operate?

Summary for ferrous citrate, fe-59

Recent Clinical Trials for ferrous citrate, fe-59

US Patents and Regulatory Information for ferrous citrate, fe-59

Ferrous Citrate, Fe-59: Market Dynamics and Financial Trajectory